Percheron Therapeutics Limited has released a press release.
ATL1102 tox study to support clinical program in the US
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Dosing commenced in DMD combination therapy study
- ATL1102 Revised Clinical Development Plans Presentation
- ATL1102 Revised Plans accelerate reporting of unblinded data
- Appendix 4E and Full Year Statutory Accounts
- Long COVID study identifies diagnostic & therapeutic targets
Later from Percheron Therapeutics
- Antisense Therapeutics CEO announces retirement
- Positive outcomes in DMD combination therapy animal study
- Limb Girdle Muscular Dystrophy R2 animal study commenced
- First approval for ATL1102 Phase IIb DMD clinical trial
- Receipt of R&D Tax Incentive Payment
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics